Spanish pharma Grifols buys plasma assets from Green Cross for $460 mln

GC Biopharma

20/07/2020 07:36

MADRID, July 20 (Reuters) - Spanish pharmaceutical company
Grifols said on Monday it agreed to buy plasma assets in North
America from South Korea's Green Cross for $460 million.
    Grifols will buy a plasma fractionation plant in Canada and
two purification facilities and 11 plasma collection centres in
the United States, the company said in a statement.
    The Barcelona-based firm will need no new financing to carry
out the acquisition, it said.
    Grifols is one of the world's top producers of treatments
based on human plasma.

 (Reporting by Inti Landauro; editing by Jason Neely)
 ((Inti.Landauro@thomsonreuters.com;))